Evidence map›Paper›PMID 32332985›Full record

ReviewNature reviews. Neurology2020

Parkinson disease and the immune system - associations, mechanisms and therapeutics.

Eng-King Tan, Yin-Xia Chao, Andrew West, Ling-Ling Chan, Werner Poewe, Joseph Jankovic

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04995081 (A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease), which is not on this map. Cited by 261 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
261citing papers in PubMed, 10 pooled it
23.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04995081 phase2completednot on this mapstarted 2021, after this paper: background citation

A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease

TypeinterventionalSponsorHope Biosciences Research FoundationRan2021 to 2025Enrolled60ConditionsParkinson DiseaseArmsBiological/Vaccine: Allogeneic HB-adMSCs, Placebo
3 · Its place in the literature

Who cites it

261 citing papers in PubMed, 10 syntheses or guidelines pooled it, 455 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Lifestyle medicine for neuroprotection: evidence and implementation in Asian contexts.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  12. Review
  13. Integration of TSPO PET and fluid biomarkers to assess neuroinflammation in Parkinson's disease.European journal of nuclear medicine and molecular imaging · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Progress of Immunotherapies in Parkinson's Disease.CNS neuroscience & therapeutics · 2026
    Review
  19. Review
  20. Article

201 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Eng-King TanDepartment of Neurology, Singapore General Hospital, Singapore, Singapore. gnrtek@sgh.com.sg.ORCID 0000-0003-2977-9743
Yin-Xia ChaoDepartment of Neurology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0003-1185-3511
Andrew WestDuke Center for Neurodegeneration and Neurotherapeutics, Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
Ling-Ling ChanDuke-NUS Medical School, Singapore, Singapore.
Werner PoeweDepartment of Neurology, Medical University Innsbruck, Innsbruck, Austria.
Joseph JankovicParkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
Singapore General Hospital · SGBaylor College of Medicine · USDuke University · USInnsbruck Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple lines of evidence indicate that immune system dysfunction has a role in Parkinson disease (PD); this evidence includes clinical and genetic associations between autoimmune disease and PD, impaired cellular and humoral immune responses in PD, imaging evidence of inflammatory cell activation and evidence of immune dysregulation in experimental models of PD. However, the mechanisms that link the immune system with PD remain unclear, and the temporal relationships of innate and adaptive immune responses with neurodegeneration are unknown. Despite these challenges, our current knowledge provides opportunities to develop immune-targeted therapeutic strategies for testing in PD, and clinical studies of some approaches are under way. In this Review, we provide an overview of the clinical observations, preclinical experiments and clinical studies that provide evidence for involvement of the immune system in PD and that help to define the nature of this association. We consider autoimmune mechanisms, central and peripheral inflammatory mechanisms and immunogenetic factors. We also discuss the use of this knowledge to develop immune-based therapeutic approaches, including immunotherapy that targets α-synuclein and the targeting of immune mediators such as inflammasomes. We also consider future research and clinical trials necessary to maximize the potential of targeting the immune system.

Indexed as

AnimalsAutoimmunityBrainHumansImmune SystemImmunotherapyNeuroimmunomodulationParkinson Disease

Identifiers

PMID32332985
OpenAlexW3019480645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.